ENB Therapeutics articles

ENB Therapeutics reports preliminary data from the ongoing Phase 1/2 trial assessing the safety and efficacy of lead product ENB-003 in combination with pembrolizumab. Safety data are encouraging with no significant drug related safety events from the first 3 dosing cohorts. Best overall responses from the first 6 patients include 2 disease stabilizations and 1 confirmed partial response. The most encouraging responses were observed in 2 patients with platinum-resistant ovarian cancer who dem